Philip Newsome BSc, MBchB, MBBS, PhD, FRCPE

Philip Newsome is Professor of Experimental Hepatology, Director of the Centre for Liver Research and Clinical Director of the Birmingham University Stem Cell Centre. He is area lead for Liver Regeneration and Cell Therapy in the NIHR Birmingham Liver Biomedical Research Unit and is the Chief Investigator on the EU FP7 funded MERLIN project. Merlin researchers are developing stem cell-based therapies that specifically target inflammatory components of liver disease. He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD. He is editor of a recently published textbook on Liver Transplantation, and chaired the national guidelines for liver transplantation in NAFLD. He sits on the NICE Guideline Development Group for NAFLD.
Philip has received significant grant funding from the NIHR, European Union, Wellcome Trust, UKSCF, BBSRC and the Medical Research Council. This research portfolio has led to high impact publications amongst over 60 major research papers in the fields of stem cell biology and liver disease. This has included original articles (PNAS, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet) and review articles (Gastroenterology, Journal of Hepatology).